Our ADCC and ADCP Reporter Bioassays are biologically relevant, MOA-based assays that can be used to measure the potency and stability of antibodies and other biologics that specifically bind and activate Fcγ receptors. The assays consist of Jurkat cells stably expressing the relevant Fcγ receptor variant and a luciferase gene regulated by the NFAT response element.

These bioassays overcome the limitations of more labor-intensive and variable primary cell assays. The workflow is simple, scalable, and provides a quantitative measure of ADCC and ADCP with low variability and high accuracy. 

In addition, our Lumit™ Immunoassay platform enables the detection of neonatal Fc Receptor (FcRn) binding in a simple, homogeneous, add-mix-read assay.